{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:17:15Z","timestamp":1793575035772,"version":"4.5.0"},"reference-count":209,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dermira","id":[{"id":"https:\/\/ror.org\/02ac14420","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen-Ortho Inc"},{"name":"Leo Pharma Inc","id":[{"id":"https:\/\/ror.org\/05tzrdd39","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/02f9zrr09","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Incyte Corporation"},{"name":"Janssen-Ortho Inc"},{"DOI":"10.13039\/501100008271","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05tzrdd39","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novan"},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sun Pharmaceuticals Ltd"},{"DOI":"10.13039\/100011284","name":"Valeant Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vioment"},{"name":"California Association of Winegrape Growers"},{"name":"Kyowa Hakko USA"},{"name":"Solgenix LLC"},{"name":"Elorac Inc"},{"name":"Idera Pharmaceuticals Inc","id":[{"id":"https:\/\/ror.org\/03zts9g74","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Kyowa Hakko USA"},{"name":"Solgenix LLC"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ortho Dermatologics"},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Coronado Biosciences"},{"name":"Immune Control"},{"name":"Incyte Corporation"},{"name":"Janssen-Ortho Inc"},{"name":"LEO Pharma","id":[{"id":"https:\/\/ror.org\/05tzrdd39","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Lerner Medical Devices Inc"},{"name":"Lilly ICOS LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novo Nordisk A\/S","id":[{"id":"https:\/\/ror.org\/0435rc536","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Xbiotech","id":[{"id":"https:\/\/ror.org\/035b6vx73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Xenoport Inc"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMS"},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis","id":[{"id":"https:\/\/ror.org\/02f9zrr09","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dermira","id":[{"id":"https:\/\/ror.org\/02ac14420","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kyowa Hakko Kirin Pharma Inc"},{"name":"LEO Pharma","id":[{"id":"https:\/\/ror.org\/05tzrdd39","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Menlo Therapeutics","id":[{"id":"https:\/\/ror.org\/02k5eqb88","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Pfizer","id":[{"id":"https:\/\/ror.org\/01xdqrp08","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Prothena","id":[{"id":"https:\/\/ror.org\/00w26fm43","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rhizen Inc"},{"name":"Syntimmune"},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Incyte Corporation"},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kadmon Corporation LLC","id":[{"id":"https:\/\/ror.org\/0391bdf37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Leo Pharma","id":[{"id":"https:\/\/ror.org\/05tzrdd39","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SCIDerm"},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ViDac Pharma"},{"name":"Estee Lauder","id":[{"id":"https:\/\/ror.org\/0411v1p84","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ferndale Laboratories Inc"},{"name":"Incyte","id":[{"id":"https:\/\/ror.org\/00cvzzg84","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Unigen"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis","id":[{"id":"https:\/\/ror.org\/02f9zrr09","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medimetriks Pharmaceuticals Inc"},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceutical Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leo Pharma","id":[{"id":"https:\/\/ror.org\/05tzrdd39","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Galderma Research & Development LLC"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Coherus Biosciences","id":[{"id":"https:\/\/ror.org\/00mjj2d85","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dermira","id":[{"id":"https:\/\/ror.org\/02ac14420","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis","id":[{"id":"https:\/\/ror.org\/02f9zrr09","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sun Pharmaceutical Industries Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jaad.2018.11.058","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T03:19:47Z","timestamp":1550027987000},"page":"1073-1113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":470,"title":["Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities"],"prefix":"10.1016","volume":"80","author":[{"given":"Craig A.","family":"Elmets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig L.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M.R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lichten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Cordoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boni E.","family":"Elewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Kivelevitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kiselica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kroshinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia L.","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun L.","family":"Pathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Farley","family":"Prater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Rupani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Stoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhya","family":"Hariharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Menter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2008.09.022","article-title":"The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004","volume":"60","author":"Kurd","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3899\/jrheum.140474","article-title":"Prevalence of psoriatic arthritis in a large cohort of Brazilian patients with psoriasis","volume":"42","author":"Ranza","year":"2015","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib9","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1186\/ar4676","article-title":"Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative","volume":"16","author":"Rose","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib10","first-page":"279","article-title":"Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis","volume":"15","author":"Gisondi","year":"2005","journal-title":"Eur J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2018.11.058_bib11","first-page":"1918","article-title":"Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway","volume":"32","author":"Madland","year":"2005","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","article-title":"The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics","volume":"24","author":"Christophers","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.11.058_bib14","author":"Gladman"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","article-title":"High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires","volume":"72","author":"Haroon","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3899\/jrheum.120836","article-title":"Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis","volume":"40","author":"Walsh","year":"2013","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jaad.2014.05.010","article-title":"Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European\/North American dermatology clinics","volume":"71","author":"Mease","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients","volume":"30","author":"Torre Alonso","year":"1991","journal-title":"Br J Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/rheumatology\/23.4.246","article-title":"Psoriatic arthritis in psoriatic patients","volume":"23","author":"Scarpa","year":"1984","journal-title":"Br J Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjd.12190","article-title":"Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)","volume":"168","author":"Coates","year":"2013","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2018.11.058_bib22","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib23","doi-asserted-by":"crossref","first-page":"e20279","DOI":"10.1371\/journal.pone.0020279","article-title":"Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis","volume":"6","author":"Wittkowski","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjd.14929","article-title":"Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study)","volume":"176","author":"Mishra","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib25","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/bjd.13135","article-title":"Achilles tendon ultrasonography may detect early features of psoriatic arthropathy in patients with cutaneous psoriasis","volume":"171","author":"Pistone","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2310\/7750.2011.10101","article-title":"High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice","volume":"16","author":"Khraishi","year":"2012","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib27","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1468-3083.2009.03159.x","article-title":"Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey","volume":"23","author":"Radtke","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1468-3083.2011.03985.x","article-title":"Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis","volume":"25","author":"Yang","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/ard.2008.089441","article-title":"Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2018.11.058_bib31","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jaad.2018.11.058_bib32","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/jamadermatol.2016.2907","article-title":"Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes","volume":"152","author":"Mansouri","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","article-title":"Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study","volume":"136","author":"Lerman","year":"2017","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jaad.2018.11.058_bib34","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jaad.2018.11.058_bib35","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The risk of stroke in patients with psoriasis","volume":"129","author":"Gelfand","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib36","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.jaad.2018.11.058_bib37","doi-asserted-by":"crossref","first-page":"775.e1-6","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable risk estimate of severe psoriasis on major cardiovascular events","volume":"124","author":"Mehta","year":"2011","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jid.2017.07.841","article-title":"Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study","volume":"138","author":"Noe","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2018.11.058_bib39","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","article-title":"Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate","volume":"76","author":"Wu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib41","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4161\/derm.23100","article-title":"Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date","volume":"4","author":"Tzellos","year":"2012","journal-title":"Dermatoendocrinol"},{"issue":"8","key":"10.1016\/j.jaad.2018.11.058_bib43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib44","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1468-3083.2012.04500.x","article-title":"Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12\/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"27","author":"Tzellos","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2018.11.058_bib45","first-page":"1002","article-title":"Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis","volume":"16","author":"Bissonnette","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"25","key":"10.1016\/j.jaad.2018.11.058_bib46","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1161\/CIRCULATIONAHA.107.759191","article-title":"Tumor necrosis factor-alpha and mortality in heart failure: a community study","volume":"118","author":"Dunlay","year":"2008","journal-title":"Circulation"},{"issue":"4 Suppl","key":"10.1016\/j.jaad.2018.11.058_bib48","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.ahj.2009.07.017","article-title":"New York Heart Association functional class predicts exercise parameters in the current era","volume":"158","author":"Russell","year":"2009","journal-title":"Am Heart J"},{"issue":"19","key":"10.1016\/j.jaad.2018.11.058_bib49","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"25 Suppl 2","key":"10.1016\/j.jaad.2018.11.058_bib50","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"25 Pt B","key":"10.1016\/j.jaad.2018.11.058_bib51","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/annrheumdis-2012-202424","article-title":"Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study","volume":"73","author":"Ogdie","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"25 Pt B","key":"10.1016\/j.jaad.2018.11.058_bib53","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"25 Pt B","key":"10.1016\/j.jaad.2018.11.058_bib55","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jaad.2018.11.058_bib56","doi-asserted-by":"crossref","first-page":"778","DOI":"10.7326\/M15-2223","article-title":"Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement","volume":"163","author":"Siu","year":"2015","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jaad.2018.11.058_bib57","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/M15-2345","article-title":"Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement","volume":"163","author":"Siu","year":"2015","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2018.11.058_bib58","first-page":"S14","article-title":"Standards of medical care in diabetes\u20132014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaad.2018.11.058_bib59","first-page":"1","article-title":"Integrated approach to comorbidity in patients with psoriasis. Working Group on Psoriasis-Associated Comorbidities [Spanish]","volume":"103 Suppl 1","author":"Dauden","year":"2012","journal-title":"Actas Dermosifiliogr"},{"issue":"17","key":"10.1016\/j.jaad.2018.11.058_bib60","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib61","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jcp.2007.048363","article-title":"Clinical and laboratory diagnosis of the metabolic syndrome","volume":"61","author":"Olufadi","year":"2008","journal-title":"J Clin Pathol"},{"issue":"9","key":"10.1016\/j.jaad.2018.11.058_bib62","doi-asserted-by":"crossref","first-page":"e105056","DOI":"10.1371\/journal.pone.0105056","article-title":"Prevalence of metabolic syndrome: association with risk factors and cardiovascular complications in an urban population","volume":"9","author":"Moreira","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12889-017-4041-1","article-title":"Prevalence and trends of metabolic syndrome among adults in the Asia-Pacific region: a systematic review","volume":"17","author":"Ranasinghe","year":"2017","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib64","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2006.09.032","article-title":"Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies","volume":"49","author":"Gami","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib65","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/HJH.0b013e32835bcce1","article-title":"The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Hypertens"},{"issue":"3 Pt 1","key":"10.1016\/j.jaad.2018.11.058_bib66","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib67","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","article-title":"Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies","volume":"68","author":"Armstrong","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"9492","key":"10.1016\/j.jaad.2018.11.058_bib68","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(05)67483-1","article-title":"Obesity","volume":"366","author":"Haslam","year":"2005","journal-title":"Lancet"},{"issue":"2 Pt 2","key":"10.1016\/j.jaad.2018.11.058_bib69","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcmg.2017.08.014","article-title":"Visceral adiposity in psoriasis is associated with vascular inflammation by (18)F-fluorodeoxyglucose positron-emission tomography\/computed tomography beyond cardiometabolic disease risk factors in an observational cohort study","volume":"11","author":"Rivers","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jaad.2018.11.058_bib70","series-title":"Obesity: preventing and managing the global epidemic","year":"2000"},{"issue":"7244","key":"10.1016\/j.jaad.2018.11.058_bib71","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/bmj.320.7244.1240","article-title":"Establishing a standard definition for child overweight and obesity worldwide: international survey","volume":"320","author":"Cole","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2018.11.058_bib72","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diabetes"},{"issue":"7","key":"10.1016\/j.jaad.2018.11.058_bib73","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","article-title":"Effect of weight loss on the severity of psoriasis: a randomized clinical study","volume":"149","author":"Jensen","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib74","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamasurg.2016.4610","article-title":"Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery","volume":"152","author":"Egeberg","year":"2017","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib75","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib76","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jaad.2018.11.058_bib77","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.12235","article-title":"Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study","volume":"168","author":"Gisondi","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib78","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/jdv.12066","article-title":"Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study","volume":"28","author":"Mahe","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib79","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamacardio.2018.0005","article-title":"The 2017 American College of Cardiology\/American Heart Association clinical practice guideline for high blood pressure in adults","volume":"3","author":"Whelton","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2340\/00015555-0741","article-title":"Psoriasis and hypertension: a case-control study","volume":"90","author":"Cohen","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2340\/00015555-0770","article-title":"Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany","volume":"90","author":"Augustin","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib82","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamadermatol.2014.2094","article-title":"Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom","volume":"151","author":"Takeshita","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib83","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2008.08563.x","article-title":"Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study","volume":"158","author":"Brauchli","year":"2008","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2018.11.058_bib84","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamadermatol.2013.9957","article-title":"Hypertension, antihypertensive medication use, and risk of psoriasis","volume":"150","author":"Wu","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib85","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1001\/archderm.143.12.1559","article-title":"Incidence and risk factors for psoriasis in the general population","volume":"143","author":"Huerta","year":"2007","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib86","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.amjcard.2007.03.058","article-title":"Prevention of renal dysfunction and hypertension by amlodipine after heart transplant","volume":"100","author":"Leenen","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaad.2018.11.058_bib87","unstructured":"Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. Available at: https:\/\/www.ahajournals.org\/cms\/attachment\/069caaec-0338-4b71-8182-9e841cb8c509\/01.cir.0000437738.63853.7av1.pdf. Accessed March 7, 2019."},{"issue":"18","key":"10.1016\/j.jaad.2018.11.058_bib88","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.116.021407","article-title":"Recent update to the US cholesterol treatment guidelines: a comparison with international guidelines","volume":"133","author":"Nayor","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib89","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","article-title":"Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis","volume":"159","author":"Kaye","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib90","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1346-8138.2009.00777.x","article-title":"Comorbidities associated with psoriasis: an experience from the Middle East","volume":"37","author":"Al-Mutairi","year":"2010","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib91","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2012.06.068","article-title":"Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis","volume":"224","author":"Mehta","year":"2012","journal-title":"Atherosclerosis"},{"issue":"39","key":"10.1016\/j.jaad.2018.11.058_bib92","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1093\/eurheartj\/ehv339","article-title":"Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis","volume":"36","author":"Salahuddin","year":"2015","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib93","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","article-title":"Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality","volume":"145","author":"Prodanovich","year":"2009","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2018.11.058_bib94","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer","year":"2006","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib95","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000111512","article-title":"Association between psoriasis and the metabolic syndrome. A cross-sectional study","volume":"216","author":"Cohen","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.11.058_bib96","first-page":"e4","article-title":"Reprint: 2013 ACC\/AHA guideline on the assessment of cardiovascular risk","year":"2013","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"8","key":"10.1016\/j.jaad.2018.11.058_bib98","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib99","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/2013.jamadermatol.406","article-title":"Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: a prospective population-based cohort study","volume":"78","author":"Wan","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib101","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jaad.2015.02.1095","article-title":"Psoriasis and risk of diabetes-associated microvascular and macrovascular complications","volume":"72","author":"Armstrong","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.11.058_bib102","first-page":"S11","article-title":"Standards of medical care in diabetes\u20132013","volume":"36 Suppl 1","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaad.2018.11.058_bib103","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4158\/EP.12.S1.20","article-title":"An update on the Diabetes Prevention Program","volume":"12 Suppl 1","author":"Ratner","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jaad.2018.11.058_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2012.04576.x","article-title":"A framework for improving the quality of care for people with psoriasis","volume":"26 Suppl 4","author":"Augustin","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2018.11.058_bib105","first-page":"1","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jaad.2018.11.058_bib106","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2016.05.043","article-title":"Self-reported depression in psoriasis is associated with subclinical vascular diseases","volume":"251","author":"Aberra","year":"2016","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib107","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and\u00a0meta-analysis","volume":"134","author":"Dowlatshahi","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib108","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","article-title":"Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys","volume":"47","author":"Helmick","year":"2014","journal-title":"Am J Prev Med"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib110","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1468-3083.2009.03321.x","article-title":"Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study","volume":"23","author":"Dauden","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib111","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2340\/00015555-1096","article-title":"Positive effect of modified Goeckerman regimen on quality of life and psychosocial distress in moderate and severe psoriasis","volume":"91","author":"Chern","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib112","first-page":"183","article-title":"Understanding the relationship between pruritus severity and work productivity in patients with moderate-to-severe psoriasis: sleep problems are a mediating factor","volume":"15","author":"Kimball","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib113","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib114","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jaad.2009.07.022","article-title":"The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized\u00a0clinical trial","volume":"62","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"9504","key":"10.1016\/j.jaad.2018.11.058_bib115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.11.058_bib116","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","article-title":"Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2018.11.058_bib117","first-page":"891","article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study","volume":"146","author":"Kurd","year":"2010","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib118","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: a systematic review and meta-analysis","volume":"77","author":"Singh","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib119","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40257-017-0281-1","article-title":"Risk of suicidality in people with psoriasis: a systematic review and meta-analysis of cohort studies","volume":"18","author":"Chi","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib120","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jaad.2010.10.020","article-title":"The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis","volume":"66","author":"Kimball","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib121","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib123","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000109357","article-title":"Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults","volume":"216","author":"Bo","year":"2008","journal-title":"Dermatology"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib124","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archderm.141.12.1580","article-title":"Relationship between smoking and the clinical severity of psoriasis","volume":"141","author":"Fortes","year":"2005","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1203475415616073","article-title":"Psoriasis and smoking: a systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity","volume":"20","author":"Richer","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib126","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1468-3083.2002.00467.x","article-title":"Assessment of depression in subjects with psoriasis vulgaris and lichen planus","volume":"16","author":"Akay","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000265557","article-title":"Smoking and alcohol intake in severely affected patients with psoriasis in Germany","volume":"220","author":"Gerdes","year":"2010","journal-title":"Dermatology"},{"issue":"6727","key":"10.1016\/j.jaad.2018.11.058_bib128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/bmj.300.6727.780","article-title":"Alcohol intake: a risk factor for psoriasis in young and middle aged men?","volume":"300","author":"Poikolainen","year":"1990","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib129","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2340\/00015555-0711","article-title":"Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis","volume":"89","author":"Wolk","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.11.058_bib130","first-page":"182","article-title":"Dietary behaviour in psoriatic patients","volume":"146","author":"Zamboni","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib131","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamadermatol.2017.3225","article-title":"Alcohol-related mortality in patients with psoriasis: a population-based cohort study","volume":"153","author":"Parisi","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib132","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.0022-202X.2005.23681.x","article-title":"Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study","volume":"125","author":"Naldi","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2018.11.058_bib133","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/1346-8138.13841","article-title":"Internalized stigma in psoriasis: a multicenter study","volume":"44","author":"Alpsoy","year":"2017","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib134","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jaad.2016.10.040","article-title":"Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis","volume":"76","author":"Hawro","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2018.11.058_bib135","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-4362.1995.tb04656.x","article-title":"Age and gender differences in the impact of psoriasis on quality of life","volume":"34","author":"Gupta","year":"1995","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib136","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2340\/00015555-1273","article-title":"IDI Mmultipurpose Psoriasis Research of Vital Experiences investigators. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life","volume":"92","author":"Sampogna","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib137","first-page":"15","article-title":"The psychological and social burdens of psoriasis","volume":"17","author":"Young","year":"2005","journal-title":"Dermatol Nurs"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib138","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2007.07881.x","article-title":"Psoriasis has a major secondary impact on the lives of family members and partners","volume":"156","author":"Eghlileb","year":"2007","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib139","doi-asserted-by":"crossref","first-page":"e52935","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011","volume":"7","author":"Armstrong","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib140","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ced.12841","article-title":"Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA","volume":"41","author":"Korman","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib141","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jaad.2008.06.043","article-title":"The impact of psoriasis on health care costs and patient work loss","volume":"59","author":"Fowler","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib142","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamadermatol.2016.0269","article-title":"Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials","volume":"152","author":"Armstrong","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib143","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3109\/09546634.2016.1165339","article-title":"A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment","volume":"27","author":"Beroukhim","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib144","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/09546634.2010.499931","article-title":"Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2","volume":"22","author":"Reich","year":"2011","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib145","first-page":"381","article-title":"Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis","volume":"17","author":"Reich","year":"2007","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib146","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF03261868","article-title":"Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting","volume":"10","author":"Vender","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib147","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","article-title":"Genital psoriasis is associated with significant impairment in quality of life and sexual functioning","volume":"72","author":"Ryan","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib148","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/jdv.12845","article-title":"Sexual dysfunction in psoriasis: a systematic review","volume":"29","author":"Molina-Leyva","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib149","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1365-4362.1997.00032.x","article-title":"Psoriasis and sex: a study of moderately to severely affected patients","volume":"36","author":"Gupta","year":"1997","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2018.11.058_bib150","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1346-8138.2006.00179.x","article-title":"Sexual dysfunction in patients with psoriasis","volume":"33","author":"Turel Ermertcan","year":"2006","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib151","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/jsm.12003","article-title":"Psoriasis and sexual behavior in U.S. women: an epidemiologic analysis using the National Health and Nutrition Examination Survey (NHANES)","volume":"10","author":"Armstrong","year":"2013","journal-title":"J Sex Med"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib152","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/jsm.12199","article-title":"Psoriasis and sexual behavior in men: examination of the National Health and Nutrition Examination Survey (NHANES) in the United States","volume":"11","author":"Armstrong","year":"2014","journal-title":"J Sex Med"},{"issue":"8","key":"10.1016\/j.jaad.2018.11.058_bib153","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/jdv.13625","article-title":"Sex and the PASI: patients affected by a mild form of psoriasis are more predisposed to have a more severe form of erectile dysfunction","volume":"30","author":"Bardazzi","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib154","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1684\/ejd.2014.2388","article-title":"Erectile dysfunction in psoriasis patients","volume":"24","author":"Cabete","year":"2014","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib155","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1743-6109.2012.02767.x","article-title":"Increased risk of sexual dysfunction in male patients with psoriasis: a nationwide population-based follow-up study","volume":"10","author":"Chen","year":"2013","journal-title":"J Sex Med"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib157","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1468-3083.2008.03031.x","article-title":"Psoriasis associated with ulcerative colitis and Crohn's disease","volume":"23","author":"Cohen","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2018.11.058_bib158","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib159","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2009.02.015","article-title":"The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis","volume":"61","author":"Makredes","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/ije\/22.2.268","article-title":"Risk indicators for inflammatory bowel disease","volume":"22","author":"Persson","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib161","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2133.1982.tb01731.x","article-title":"Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis","volume":"106","author":"Yates","year":"1982","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib162","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1590\/S0004-28032012000200014","article-title":"The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?","volume":"49","author":"Denadai","year":"2012","journal-title":"Arq Gastroenterol"},{"issue":"8","key":"10.1016\/j.jaad.2018.11.058_bib163","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/ajg.2015.205","article-title":"Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience","volume":"110","author":"Freling","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib164","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","article-title":"Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study","volume":"22","author":"Guerra","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib165","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"20","key":"10.1016\/j.jaad.2018.11.058_bib166","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.11.058_bib167","series-title":"STELARA [package insert]","year":"2016"},{"issue":"11","key":"10.1016\/j.jaad.2018.11.058_bib168","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib169","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaad.2010.04.046","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan","volume":"65","author":"Chen","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2133.1999.02655.x","article-title":"Malignant tumours and psoriasis: a follow-up study","volume":"140","author":"Frentz","year":"1999","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib171","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1523-1747.2000.00898.x","article-title":"Psoriasis, its treatment, and cancer in a cohort of Finnish patients","volume":"114","author":"Hannuksela-Svahn","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib172","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1365-4632.2011.05310.x","article-title":"The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study","volume":"51","author":"Lee","year":"2012","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib173","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib174","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in The Health Improvement Network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.11.058_bib175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27 Suppl 3","author":"Pouplard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib176","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib177","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib178","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","article-title":"The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials","volume":"12","author":"Leonardi","year":"2011","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib179","first-page":"1441","article-title":"Safety observations in 12,095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies","volume":"13","author":"Gottlieb","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib180","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib181","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2011.06.011","article-title":"Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials","volume":"66","author":"Lebwohl","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib182","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib183","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.11.058_bib185","doi-asserted-by":"crossref","first-page":"f5961","DOI":"10.1136\/bmj.f5961","article-title":"Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study","volume":"347","author":"Wan","year":"2013","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib186","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jdermsci.2015.03.012","article-title":"Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study","volume":"78","author":"Chi","year":"2015","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib187","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjd.13599","article-title":"Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study","volume":"173","author":"Chiu","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib188","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11255-011-9966-1","article-title":"The spectrum of renal abnormalities in patients with psoriasis","volume":"44","author":"Dervisoglu","year":"2012","journal-title":"Int Urol Nephrol"},{"issue":"7","key":"10.1016\/j.jaad.2018.11.058_bib189","first-page":"809","article-title":"Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study","volume":"95","author":"Svedbom","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib190","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/bjd.14961","article-title":"The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study","volume":"176","author":"Grewal","year":"2017","journal-title":"Br J Dermatol"},{"issue":"25","key":"10.1016\/j.jaad.2018.11.058_bib191","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1056\/NEJM199206183262502","article-title":"Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases","volume":"326","author":"Feutren","year":"1992","journal-title":"N Engl J Med"},{"issue":"3 Pt 1","key":"10.1016\/j.jaad.2018.11.058_bib192","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0190-9622(89)70209-7","article-title":"Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function","volume":"21","author":"Gilbert","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.058_bib193","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2125.2002.01621.x","article-title":"Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis","volume":"54","author":"Chladek","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib194","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cpdd.256","article-title":"Impact of renal impairment on the pharmacokinetics of apremilast and metabolite M12","volume":"5","author":"Liu","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib195","doi-asserted-by":"crossref","first-page":"663","DOI":"10.5664\/jcsm.5790","article-title":"Psoriasis and sleep apnea: a Danish nationwide cohort study","volume":"12","author":"Egeberg","year":"2016","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"10.1016\/j.jaad.2018.11.058_bib196","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1111\/ijd.13367","article-title":"Psoriasis and obstructive sleep apnea","volume":"55","author":"Shalom","year":"2016","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib197","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.sleep.2011.07.018","article-title":"Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study","volume":"13","author":"Yang","year":"2012","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib198","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/09546634.2012.713458","article-title":"Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial","volume":"25","author":"Maari","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.058_bib199","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/bjd.12000","article-title":"Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label phase IIIB trial","volume":"167","author":"Strober","year":"2012","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib200","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/09546634.2015.1107180","article-title":"Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"27","author":"Ungprasert","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib201","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1365-2133.2008.08749.x","article-title":"Psoriasis and chronic obstructive pulmonary disease: a case-control study","volume":"159","author":"Dreiher","year":"2008","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.058_bib202","doi-asserted-by":"crossref","first-page":"e0145221","DOI":"10.1371\/journal.pone.0145221","article-title":"Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib203","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1468-3083.2011.04009.x","article-title":"Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan","volume":"26","author":"Chiang","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2018.11.058_bib204","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.058_bib205","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/jamaophthalmol.2017.0569","article-title":"Risk of uveitis among people with psoriasis: a nationwide cohort study","volume":"135","author":"Chi","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.jaad.2018.11.058_bib206","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jamadermatol.2015.1986","article-title":"Association of psoriatic disease with uveitis: a Danish nationwide cohort study","volume":"151","author":"Egeberg","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.058_bib207","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/09273940802023786","article-title":"Biologic response modifier therapy for psoriatic ocular inflammatory disease","volume":"16","author":"Huynh","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jaad.2018.11.058_bib209","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/ced.12672","article-title":"Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease","volume":"40","author":"Abedini","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib210","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","article-title":"Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Miele","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaad.2018.11.058_bib211","doi-asserted-by":"crossref","first-page":"7963972","DOI":"10.1155\/2016\/7963972","article-title":"Liver stiffness measurement in psoriasis: do metabolic or disease factors play the important role?","volume":"2016","author":"Pongpit","year":"2016","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.jaad.2018.11.058_bib212","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.058_bib213","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3122\/jabfm.17.1.59","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature","volume":"17","author":"Ebell","year":"2004","journal-title":"J Am Board Fam Pract"},{"key":"10.1016\/j.jaad.2018.11.058_bib214","series-title":"AAD. Administrative Regulation - Evidence-Based Clinical Practice Guidelines","year":"2012"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218330020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218330020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:50:45Z","timestamp":1759272645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218330020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":209,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0190962218330020"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.11.058","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.11.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}